BTAI BioXcel Therapeutics
- 2.560
- +0.020+0.79%
- 2.600
- +0.040+1.56%
BioXcel Therapeutics News
Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertainties
BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
NEW HAVEN, Conn., April 25, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in n
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ETTrial being led by Georgetown University's Lombardi Comprehensive Cancer CenterNEW HAVEN, Conn., April 24, 2024 (GLOBE N
Express News | HC Wainwright & Co. Reiterates Buy on BioXcel Therapeutics, Maintains $10 Price Target
BioXcel Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/23/2024 250.88% HC Wainwright & Co. → $10 Reiterates Buy → Buy 03/18/2024 285.96% HC Wainwright & Co. →
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
Express News | BioXcel: Expects to Enroll About 30 Patients in Study to Evaluate Correlation Between Patient-Reported Efficacy With Trained Rater-Reported Efficacy
Express News | BioXcel Therapeutics: Outpatient Trial Expected to Enroll About 200 Patients With Agitation Associated With Bipolar Disorder or Schizophrenia
Express News | BioXcel Therapeutics: Plans to Initiate Serenity at-Home Pivotal Phase 3 Safety Trial With 120 Mcg Dose
Express News | BioXcel Therapeutics Announces Plan for Evaluating Bxcl501 in the at-Home Setting to Expand Its Market Potential
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Express News | BioXcel Therapeutics Announced Details Regarding The Planned Design Of Its Upcoming TRANQUILITY In-care Phase 3 Trial Of BXCL501 For Agitation Associated With Alzheimer's Dementia
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,811.54 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Yocca Frank sold 1,067 shares of common stock on Apr 4, 2024 at an average price of $2.635 for a total value of $2,811.54.Source: Announcement What is statement
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,667.43 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Rodriguez Javier sold 1,012 shares of common stock on Apr 4, 2024 at an average price of $2.6358 for a total value of $2,667.43.Source: Announcement What is sta
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,816.81 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Steinhart Richard I sold 1,069 shares of common stock on Apr 4, 2024 at an average price of $2.635 for a total value of $2,816.81.Source: Announcement What is s
BioXcel Therapeutics(BTAI.US) Officer Sells US$2,656.18 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Wiley Matthew T. sold 1,008 shares of common stock on Apr 4, 2024 at an average price of $2.6351 for a total value of $2,656.18.Source: Announcement What is sta
BioXcel Therapeutics(BTAI.US) Officer Sells US$13,823.02 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer Mehta Vimal sold 5,268 shares of common stock on Apr 4, 2024 at an average price of $2.624 for a total value of $13,823.02.Source: Announcement What is statemen
BioXcel Therapeutics(BTAI.US) Officer Sells US$432.48 in Common Stock
$BioXcel Therapeutics(BTAI.US)$ Officer O'Neill Vincent sold 165 shares of common stock on Apr 4, 2024 at an average price of $2.6211 for a total value of $432.48.Source: Announcement What is statemen
Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis
Analysis
Price Target
No Data
